SCHEMBL315575

SCHEMBL315575

COc1ccc2[nH][c]cc2c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AXL P30530 1/20 0.53
MEN1 O00255 4/20 0.50
KMT2A Q03164 4/20 0.50
KDM4E B2RXH2 4/20 0.50
HSD17B10 Q99714 3/20 0.50
MAPT P10636 3/20 0.50
ALDH1A1 P00352 3/20 0.50
GFER P55789 2/20 0.50
HPGD P15428 2/20 0.50
TSHR P16473 1/20 0.50
CYP1A2 P05177 1/20 0.48
CYP2A6 P11509 1/20 0.48
PDGFRB P09619 2/20 0.47
PDGFRA P16234 2/20 0.47
LOXL2 Q9Y4K0 1/20 0.47
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
PSMB8 P28062 1/20 0.46
POLB P06746 2/20 0.46
MAPK1 P28482 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL533492 0.86 MEN1 (0.53) AXLMEN1KMT2AKDM4EHSD17B10
SCHEMBL11193855 0.76 ALDH1A1 (0.57) MEN1KMT2AKDM4EHSD17B10MAPT
SCHEMBL9742331 0.74 TUBB1 (0.58) KDM4EHSD17B10MAPTTSHRMAPK1
SCHEMBL29447161 0.74 CYP1A2 (0.79) AXLMEN1KMT2AKDM4ECYP1A2
SCHEMBL443070 0.74 CYP1A2 (0.79) AXLMEN1KMT2AKDM4ECYP1A2
SCHEMBL208359 0.71 CYP1A2 (0.48) MEN1KMT2AKDM4EHSD17B10MAPT
SCHEMBL29992449 0.71 MEN1 (0.71) AXLMEN1KMT2AKDM4EHSD17B10
SCHEMBL74720 0.71 MEN1 (0.71) AXLMEN1KMT2AKDM4EHSD17B10
SCHEMBL3072814 0.71 AXL (0.58) AXLMEN1KMT2AKDM4EHSD17B10
SCHEMBL577336 0.70 EHMT2 (0.48) AXLKDM4EMAPTALDH1A1GFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 301 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3176163-B1 NOVEL INDENE DERIVATIVE, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR TREATING RETINAL DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT IAC IN NAT UNIV CHUNGNAM (KR) 2019-04-17 EP claimed
EP-2791120-B1 1,3,5 -TRIAZINE-2-AMINE DERIVATIVES, PREPARATION THEREOF AND DIAGNOSTIC AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2016-02-24 EP claimed
US-20150299163-A1 COMPOUNDS FOR USE IN THE TREATMENT OF PARASITIC DISEASES IRBM - SCIENCE PARK S.P.A. (IT) 2015-10-22 US claimed
EP-2914589-A1 COMPOUNDS FOR USE IN THE TREATMENT OF PARASITIC DISEASES IRBM - Science Park S.p.A. (IT) 2015-09-09 EP claimed
US-9115121-B2 1,3,5-triazine-2-amine derivatives, preparation thereof and diagnostic and therapeutic use thereof SANOFI (FR) 2015-08-25 US claimed
US-20140343061-A1 1,3,5 -Triazine-2-Amine Derivatives, Preparation Thereof And Diagnostic And Therapeutic Use Thereof SANOFI (FR) 2014-11-20 US claimed
EP-2791120-A1 1,3,5 -TRIAZINE-2-AMINE DERIVATIVES, PREPARATION THEREOF AND DIAGNOSTIC AND THERAPEUTIC USE THEREOF SANOFI (FR) 2014-10-22 EP claimed
WO-2014067985-A1 COMPOUNDS FOR USE IN THE TREATMENT OF PARASITIC DISEASES IRBM SCIENCE PARK S.P.A. (IT) 2014-05-08 WO claimed
WO-2013087643-A1 1,3,5 -TRIAZINE-2-AMINE DERIVATIVES, PREPARATION THEREOF AND DIAGNOSTIC AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-06-20 WO claimed
EP-2176251-B1 5-pyridinone substituted indazoles and pharmaceutical compositions thereof ALBANY MOLECULAR RES INC (US) 2012-02-08 EP claimed
US-20030176441-A1 Piperazine CCR-3 receptor antagonists ROCHE PALO ALTO LLC 2003-09-18 US claimed
WO-2003045393-A1 PIPERAZINE DERIVATIVES FOR USE AS CCR-3 RECEPTOR ANTAGONISTS IN THE TREATMENT OF ASTHMA F. HOFFMANN-LA ROCHE AG (CH) 2003-06-05 WO claimed
WO-2003045937-A1 N-UREIDO-PIPERIDINES AS ANTAGONISTS VIII FOR CCR-3 RECEPTOR F. HOFFMANN-LA ROCHE AG (CH) 2003-06-05 WO claimed
EP-0680469-B1 AMINOACID DERIVATES, MEDICAMENTS CONTAINING THESE COMPOUNDS AND PROCESS FOR PREPARING THE SAME BOEHRINGER INGELHEIM PHARMA (DE) 2000-04-26 EP claimed
US-5698576-A POSSESS ANTI-ULCER AND 5-LIPOXYGENASE INHIBITORY ACTIVITIES SANKYO COMPANY, LIMITED (JP) 1997-12-16 US claimed
JP-H08505862-A 1996-06-25 JP claimed
EP-0680469-A1 AMINOACID DERIVATES, MEDICAMENTS CONTAINING THESE COMPOUNDS AND PROCESS FOR PREPARING THE SAME Dr. Karl Thomae GmbH (DE) 1995-11-08 EP claimed
WO-1994017035-A1 AMINOACID DERIVATES, MEDICAMENTS CONTAINING THESE COMPOUNDS AND PROCESS FOR PREPARING THE SAME DR. KARL THOMAE GMBH (DE) 1994-08-04 WO claimed
EP-0422178-A1 PYRIMIDINE DERIVATIVES. ICI PLC (GB) 1991-04-17 EP claimed
US-4328227-A HYPOTENSIVE AGENTS HOECHST AKTIENGESELLSCHAFT (DE) 1982-05-04 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150299163-A1 COMPOUNDS FOR USE IN THE TREATMENT OF PARASITIC DISEASES HDAC3, HDAC5, HDAC1 AXL 2785/4885MEN1 3735/4885KMT2A 71/4885
US-20140343061-A1 1,3,5 -Triazine-2-Amine Derivatives, Preparation Thereof And Diagnostic And Therapeutic Use Thereof ALK, HRH3, HRH4 AXL 1153/4885MEN1 1357/4885KMT2A 2030/4885
US-20030176441-A1 Piperazine CCR-3 receptor antagonists CCR3, CCR1, CCRL2 AXL 1360/4885MEN1 4531/4885KMT2A 2706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.